Kindstar Globalgene Technology (HKSE:09960) Altman Z2-Score: 5.24 (As of Aug. 31, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09960 Kindstar Globalgene Technology Inc HKSE:09960
69 GF Score
Price HK$1.00
GF Value HK$1.06
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Kindstar Globalgene Technology Altman Z2-Score?

Kindstar Globalgene Technology HKSE:09960 +3.09% 69 Altman Z2-Score is 5.24 as of Aug. 31, 2026, which is 2% below its 10-year median of 5.33. GuruFocus rates HKSE:09960 with a GF Score™ of 69/100 and a GF Value™ of HK$1.06 (Fairly Valued). The stock has 6 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Kindstar Globalgene Technology ranks better than 70.41% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Kindstar Globalgene Technology has a Altman Z2-Score of 5.24, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Kindstar Globalgene Technology's Altman Z2-Score or its related term are showing as below:

HKSE:09960' s Altman Z2-Score Range Over the Past 10 Years
Min: -12.01   Med: 5.33   Max: 7.5
Current: 5.24

During the past 8 years, Kindstar Globalgene Technology's highest Altman Z2-Score was 7.50. The lowest was -12.01. And the median was 5.33.


Kindstar Globalgene Technology  (HKSE:09960) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Kindstar Globalgene Technology Altman Z2-Score Related Terms


Kindstar Globalgene Technology Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Kindstar Globalgene Technology's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kindstar Globalgene Technology Altman Z2-Score Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 7.45 6.88 7.50 5.41 5.24

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.50 0.00 5.41 0.00 5.24

HKSE:09960 vs TMO, DHR, NTRA: Altman Z2-Score Comparison

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindstar Globalgene Technology Altman Z2-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's Altman Z2-Score falls into.


HKSE:09960
69GF Score
Kindstar Globalgene Technology Inc HKSE:09960
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kindstar Globalgene Technology Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Kindstar Globalgene Technology's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.355+3.26*0+6.72*-0.0068+1.05*2.8175
=5.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was HK$4,148 Mil.
Total Current Assets was HK$2,287 Mil.
Total Current Liabilities was HK$815 Mil.
Retained Earnings was HK$0 Mil.
Pre-Tax Income was HK$-45 Mil.
Interest Expense was HK$-16 Mil.
Total Liabilities was HK$1,070 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2287.37 - 815.081)/4147.71
=0.355

X2=Retained Earnings/Total Assets
=0/4147.71
=0

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-44.614 - -16.468)/4147.71
=-0.0068

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(3015.296 - 0)/1070.209
=2.8175

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Kindstar Globalgene Technology has a Altman Z2-Score of 5.24 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 5.24 mean?
Kindstar Globalgene Technology (HKSE:09960) has a Altman Z2-Score of 5.24 as of Aug. 31, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Kindstar Globalgene Technology and its competitors. This is near median its historical median of 5.33. According to the industry distribution chart, Kindstar Globalgene Technology ranks #58 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 29.6%.
Is Kindstar Globalgene Technology's Altman Z2-Score too high?
Kindstar Globalgene Technology's current Altman Z2-Score of 5.24 is near median its 10-year median of 5.33. The Medical Diagnostics & Research industry median Altman Z2-Score is 1.69. Kindstar Globalgene Technology's value of 5.24 is 211% above this industry median. Based on the distribution chart, Kindstar Globalgene Technology ranks #58 out of 196 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's Altman Z2-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kindstar Globalgene Technology ranks #58 out of 196 companies for Altman Z2-Score. This puts Kindstar Globalgene Technology in the upper half of its industry. The industry median Altman Z2-Score is 1.69. Kindstar Globalgene Technology's value of 5.24 is 211% above this benchmark. While the company's 10-year median is 5.33 vs. the industry median of 1.69, Kindstar Globalgene Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Diagnostics & Research company?
The median Altman Z2-Score among Medical Diagnostics & Research companies is 1.69, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kindstar Globalgene Technology's current Altman Z2-Score of 5.24 is 211% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Kindstar Globalgene Technology and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z2-Score is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kindstar Globalgene Technology's current Altman Z2-Score is 5.24, which is near median its own 10-year median of 5.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current Altman Z2-Score is 5.24, which is near median its 10-year median of 5.33 and 211% above the Medical Diagnostics & Research industry median of 1.69. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current Altman Z2-Score is 5.24 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?

Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued. The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06. GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.

Key valuation signals for HKSE:09960:

  • Altman Z2-Score: 5.24 (near median its 10-year median of 5.33)
  • GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
  • GF Score™: 69/100 with 6 warning signs
  • Industry Position: 211% above the Medical Diagnostics & Research median (#58 of 196)

No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kindstar Globalgene Technology Business Description

Address Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score

Get the complete analysis for HKSE:09960

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.00
Price
HK$1.06
GF Value